WEBINAR

Friday, November 14, 2025 | 8am PDT/11am EDT


Obesity remains a critical global health threat, affecting over one billion people worldwide and exacerbating risks for type 2 diabetes, cardiovascular diseases, and fatty liver disease. The pharmaceutical landscape is witnessing rapid transformation through novel oral GLP-1 agents, long-acting injectables, and multi-target therapies that are redefining treatment possibilities.

At the preclinical stage, BioDuro's Diet-Induced Obesity (DIO) rodent models, enhanced with high-resolution phenotyping tools, create a crucial translational bridge to accelerate weight loss drug development. 


Key Topics:

Review emerging obesity targets and clinical development progress.
Compare and select optimal rodent models for obesity research.
Design effective efficacy studies for weight loss compounds.
Enhance translation between preclinical and clinical study outcomes.


Whether advancing weight loss programs or exploring novel targets, this webinar delivers practical insights to support your drug development initiatives.

Watch On-Demand


Speaker:
资源 1.png
John Liu, Ph.D.
Head of Pharmacology, 
BioDuro

✉️Contact Us
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all